Interleukin-1 blockade in heart failure with preserved ejection fraction : rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2)
© 2017 Wiley Periodicals, Inc..
Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of confirmed HF cases in the United States. However, there are no highly effective evidence-based treatments currently available for these patients. Inflammation correlates positively with adverse outcomes in HF patients. Interleukin (IL)-1, a prototypical inflammatory cytokine, has been implicated as a driver of diastolic dysfunction in preclinical animal models and a pilot clinical trial. The Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) is a phase 2, 2:1 randomized, double-blind, placebo-controlled clinical trial that will test the hypothesis that IL-1 blockade with anakinra (recombinant human IL-1 receptor antagonist) improves (1) cardiorespiratory fitness, (2) objective evidence of diastolic dysfunction, and (3) elevated inflammation in patients with HFpEF (http://www.ClinicalTrials.gov NCT02173548). The co-primary endpoints will be placebo-corrected interval changes in peak oxygen consumption and ventilatory efficiency at week 12. In addition, secondary and exploratory analyses will investigate the effects of IL-1 blockade on cardiac structure and function, systemic inflammation, endothelial function, quality of life, body composition, nutritional status, and clinical outcomes. The D-HART2 clinical trial will add to the growing body of evidence on the role of inflammation in cardiovascular disease, specifically focusing on patients with HFpEF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Clinical cardiology - 40(2017), 9 vom: 06. Sept., Seite 626-632 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Van Tassell, Benjamin W [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.06.2018 Date Revised 09.01.2021 published: Print-Electronic ClinicalTrials.gov: NCT02173548 Citation Status MEDLINE |
|---|
| doi: |
10.1002/clc.22719 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271612169 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271612169 | ||
| 003 | DE-627 | ||
| 005 | 20231224233057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/clc.22719 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0905.xml |
| 035 | |a (DE-627)NLM271612169 | ||
| 035 | |a (NLM)28475816 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Van Tassell, Benjamin W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interleukin-1 blockade in heart failure with preserved ejection fraction |b rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.06.2018 | ||
| 500 | |a Date Revised 09.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02173548 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 Wiley Periodicals, Inc. | ||
| 520 | |a Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of confirmed HF cases in the United States. However, there are no highly effective evidence-based treatments currently available for these patients. Inflammation correlates positively with adverse outcomes in HF patients. Interleukin (IL)-1, a prototypical inflammatory cytokine, has been implicated as a driver of diastolic dysfunction in preclinical animal models and a pilot clinical trial. The Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) is a phase 2, 2:1 randomized, double-blind, placebo-controlled clinical trial that will test the hypothesis that IL-1 blockade with anakinra (recombinant human IL-1 receptor antagonist) improves (1) cardiorespiratory fitness, (2) objective evidence of diastolic dysfunction, and (3) elevated inflammation in patients with HFpEF (http://www.ClinicalTrials.gov NCT02173548). The co-primary endpoints will be placebo-corrected interval changes in peak oxygen consumption and ventilatory efficiency at week 12. In addition, secondary and exploratory analyses will investigate the effects of IL-1 blockade on cardiac structure and function, systemic inflammation, endothelial function, quality of life, body composition, nutritional status, and clinical outcomes. The D-HART2 clinical trial will add to the growing body of evidence on the role of inflammation in cardiovascular disease, specifically focusing on patients with HFpEF | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Heart Failure | |
| 650 | 4 | |a Interleukin-1 | |
| 650 | 4 | |a clinical trial study design | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Cardiovascular Agents |2 NLM | |
| 650 | 7 | |a Interleukin 1 Receptor Antagonist Protein |2 NLM | |
| 650 | 7 | |a Interleukin-1 |2 NLM | |
| 700 | 1 | |a Buckley, Leo F |e verfasserin |4 aut | |
| 700 | 1 | |a Carbone, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Trankle, Cory R |e verfasserin |4 aut | |
| 700 | 1 | |a Canada, Justin M |e verfasserin |4 aut | |
| 700 | 1 | |a Dixon, Dave L |e verfasserin |4 aut | |
| 700 | 1 | |a Abouzaki, Nayef |e verfasserin |4 aut | |
| 700 | 1 | |a Oddi-Erdle, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Biondi-Zoccai, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Arena, Ross |e verfasserin |4 aut | |
| 700 | 1 | |a Abbate, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cardiology |d 1992 |g 40(2017), 9 vom: 06. Sept., Seite 626-632 |w (DE-627)NLM000419834 |x 1932-8737 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2017 |g number:9 |g day:06 |g month:09 |g pages:626-632 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/clc.22719 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2017 |e 9 |b 06 |c 09 |h 626-632 | ||